Therefore, more key clinical markers such as AFP levels, genetic mutations, or immune markers should be incorporated with imaging features in order to enhance the model’s prognostic power and create a more comprehensive, multi-modal prediction tool for early recurrence of MVI-negative HCC in the future. This evidence concerns the gene AFP and hepatocellular carcinoma.